Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study-Reference-Cited by-同舟云学术

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Published:2015-09 Issue:9 Volume:16 Page:1099-1110
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Issa Jean-Pierre J,Roboz Gail,Rizzieri David,Jabbour Elias,Stock Wendy,O'Connell Casey,Yee Karen,Tibes Raoul,Griffiths Elizabeth A,Walsh Katherine,Daver Naval,Chung Woonbok,Naim Sue,Taverna Pietro,Oganesian Aram,Hao Yong,Lowder James N,Azab Mohammad,Kantarjian Hagop

Funder

Astex Pharmaceuticals and, in part, by a Stand Up To Cancer Dream Team Translational Research Grant

Publisher

Elsevier BV

Subject

Oncology

Reference17 articles.

1. The fundamental role of epigenetic events in cancer;Jones;Nat Rev Genet,2002

2. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy;Jabbour;Cancer,2010

3. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy;Karahoca;Clin Epigenetics,2013

4. Targeting DNA methylation;Issa;Clin Cancer Res,2009

5. Bioavailability of azacitidine subcutaneous versus intravenous in patients with myelodysplastic syndromes;Marcucci;J Clin Pharmacol,2005

Cited by 254 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies;Critical Reviews in Oncology/Hematology;2024-09

2. Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review);Molecular and Clinical Oncology;2024-06-28

3. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment;Pharmacological Research;2024-06

4. Alteration in DNA methylation patterns: Epigenetic signatures in gastrointestinal cancers;European Journal of Pharmacology;2024-06

5. Therapeutic targeting of DNA methylation alterations in cancer;Pharmacology & Therapeutics;2024-06